NIH Genome Institute makes two leadership appointments
This article was originally published in Scrip
The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, has appointed two senior staff to leadership positions. Dr Mark Guyer, currently director of NHGRI's division of extramural research, has been appointed deputy director of the institute, and Dr James Mullikin, currently acting director of the NIH Intramural Sequencing Center, has been kept on as its permanent director. Dr Guyer has served at NHGRI for 23 years, and Dr Mullikin joined the NIH in 2003.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.